DauntlessPharmaceuticals

Traditional biotechnology companies own numerous assets at different stages of development, with investors, management, laboratories, and employees sharing a common interest in all company assets. It was established to develop DP1038, an intranasal octreotide formulation, as a therapeutic drug for acromegaly, neuroendocrine tumors, and other gastrointestinal-related diseases.